243 related articles for article (PubMed ID: 23836045)
21. AIDS preclinical vaccine development: biennial survey of HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates.
Warren JT; Levinson MA
J Med Primatol; 1999; 28(4-5):249-73. PubMed ID: 10593492
[No Abstract] [Full Text] [Related]
22. Current advances in HIV vaccine preclinical studies using Macaque models.
Liang B; Li H; Li L; Omange RW; Hai Y; Luo M
Vaccine; 2019 Jun; 37(26):3388-3399. PubMed ID: 31088747
[TBL] [Abstract][Full Text] [Related]
23. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ
J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957
[TBL] [Abstract][Full Text] [Related]
24. The role of nonhuman primates in the development of an AIDS vaccine.
Nathanson N; Hirsch VM; Mathieson BJ
AIDS; 1999; 13 Suppl A():S113-20. PubMed ID: 10885770
[TBL] [Abstract][Full Text] [Related]
25. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.
Fouts TR; Bagley K; Prado IJ; Bobb KL; Schwartz JA; Xu R; Zagursky RJ; Egan MA; Eldridge JH; LaBranche CC; Montefiori DC; Le Buanec H; Zagury D; Pal R; Pavlakis GN; Felber BK; Franchini G; Gordon S; Vaccari M; Lewis GK; DeVico AL; Gallo RC
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):E992-9. PubMed ID: 25681373
[TBL] [Abstract][Full Text] [Related]
26. Candidate vaccines protect macaques against primate immunodeficiency viruses.
Stott J; Hu SL; Almond N
AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S265-70. PubMed ID: 9814954
[TBL] [Abstract][Full Text] [Related]
27. Accelerating HIV vaccine development using non-human primate models.
Rahman MA; Robert-Guroff M
Expert Rev Vaccines; 2019 Jan; 18(1):61-73. PubMed ID: 30526159
[TBL] [Abstract][Full Text] [Related]
28. Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.
Page M; Stebbings R; Berry N; Hull R; Ferguson D; Davis L; Duffy L; Elsley W; Hall J; Ham C; Hassall M; Li B; Mee ET; Quartey-Papafio R; Rose NJ; Mathy N; Voss G; Stott EJ; Almond N
Retrovirology; 2012 Jul; 9():56. PubMed ID: 22799593
[TBL] [Abstract][Full Text] [Related]
29. HIV vaccine research and discovery in the nonhuman primates model: a unified theory in acquisition prevention and control of SIV infection.
Lynch RM; Yamamoto T; McDermott AB
Curr Opin HIV AIDS; 2013 Jul; 8(4):288-94. PubMed ID: 23666390
[TBL] [Abstract][Full Text] [Related]
30. Progress toward an HIV vaccine.
Letvin NL
Annu Rev Med; 2005; 56():213-23. PubMed ID: 15660510
[TBL] [Abstract][Full Text] [Related]
31. Towards an AIDS vaccine: the role of primate models.
Nathanson N
Int J STD AIDS; 1998; 9 Suppl 1():3-7. PubMed ID: 9874107
[TBL] [Abstract][Full Text] [Related]
32. Is an HIV vaccine possible?
Wilson NA; Watkins DI
Braz J Infect Dis; 2009 Aug; 13(4):304-10. PubMed ID: 20231996
[TBL] [Abstract][Full Text] [Related]
33. Prospects for a Globally Effective HIV-1 Vaccine.
Excler JL; Robb ML; Kim JH
Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S307-18. PubMed ID: 26590431
[TBL] [Abstract][Full Text] [Related]
34. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
O'Connell RJ; Kim JH; Excler JL
Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695
[TBL] [Abstract][Full Text] [Related]
35. Mucosal Vaccination for Prevention of HIV Infection and AIDS.
Aldovini A
Curr HIV Res; 2016; 14(3):247-59. PubMed ID: 26957199
[TBL] [Abstract][Full Text] [Related]
36. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.
Ringel O; Vieillard V; Debré P; Eichler J; Büning H; Dietrich U
Viruses; 2018 Apr; 10(4):. PubMed ID: 29662026
[TBL] [Abstract][Full Text] [Related]
37. First updated and revised survey of worldwide HIV and SIV vaccine challenge studies in nonhuman primates: progress in first and second order studies.
Warren JT; Dolatshahi M
J Med Primatol; 1993; 22(2-3):203-35. PubMed ID: 8411110
[No Abstract] [Full Text] [Related]
38. Adenoviruses as vectors for HIV vaccines.
Gómez-Román VR; Robert-Guroff M
AIDS Rev; 2003; 5(3):178-85. PubMed ID: 14598567
[TBL] [Abstract][Full Text] [Related]
39. No acquisition: a new ambition for HIV vaccine development?
Lakhashe SK; Silvestri G; Ruprecht RM
Curr Opin Virol; 2011 Oct; 1(4):246-53. PubMed ID: 22081778
[TBL] [Abstract][Full Text] [Related]
40. Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates.
Warren J
J Med Primatol; 2002 Aug; 31(4-5):237-56. PubMed ID: 12390546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
